MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

CareDx Inc

Gesloten

SectorGezondheidszorg

20.03 -2.72

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

19.98

Max

20.51

Belangrijke statistieken

By Trading Economics

Inkomsten

-88M

-10M

Verkoop

-1.9M

85M

K/W

Sectorgemiddelde

16.473

39.564

Winstmarge

-12.225

Werknemers

644

EBITDA

-6.1M

-13M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+19.58% upside

Dividenden

By Dow Jones

Volgende Winsten

30 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

16M

1B

Vorige openingsprijs

22.75

Vorige sluitingsprijs

20.03

Nieuwssentiment

By Acuity

41%

59%

147 / 376 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

CareDx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 jul 2025, 22:19 UTC

Acquisities, Fusies, Overnames

FCC Approves U.S. Cellular Sale to T-Mobile

11 jul 2025, 17:28 UTC

Belangrijke Marktbewegers

SharpLink Gaming Gains on Ethereum Purchase

11 jul 2025, 16:57 UTC

Winsten

BASF Cuts Outlook on Global Economy Uncertainty

11 jul 2025, 21:45 UTC

Marktinformatie

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 jul 2025, 19:46 UTC

Acquisities, Fusies, Overnames

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 jul 2025, 19:45 UTC

Marktinformatie

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 jul 2025, 19:05 UTC

Marktinformatie

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 jul 2025, 18:18 UTC

Marktinformatie

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 jul 2025, 17:35 UTC

Marktinformatie

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 jul 2025, 17:26 UTC

Marktinformatie

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 jul 2025, 16:53 UTC

Marktinformatie

Crude Futures Add to Early Gains -- Market Talk

11 jul 2025, 16:42 UTC

Winsten

BASF Cuts Outlook on Global Economic Uncertainty

11 jul 2025, 16:08 UTC

Marktinformatie

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 jul 2025, 16:05 UTC

Winsten

BASF Will Publish Half-Year Results on July 30

11 jul 2025, 16:04 UTC

Marktinformatie

Global Equities Roundup: Market Talk

11 jul 2025, 16:04 UTC

Marktinformatie

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11 jul 2025, 16:03 UTC

Winsten

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11 jul 2025, 16:02 UTC

Winsten

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11 jul 2025, 16:01 UTC

Winsten

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11 jul 2025, 16:00 UTC

Winsten

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11 jul 2025, 15:59 UTC

Winsten

BASF Cuts 2025 Earnings View

11 jul 2025, 15:58 UTC

Winsten

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11 jul 2025, 15:57 UTC

Winsten

BASF 2Q EBIT Before Special Items EUR810M

11 jul 2025, 15:54 UTC

Winsten

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11 jul 2025, 15:54 UTC

Winsten

BASF 2Q Sales Fell 2.1% on Year

11 jul 2025, 15:53 UTC

Winsten

BASF 2Q Sales EUR15.77B

11 jul 2025, 15:52 UTC

Winsten

BASF: This Was in Line With Consensus Estimates

11 jul 2025, 15:52 UTC

Winsten

BASF 2Q Ebitda Before Special Items EUR1.77B

11 jul 2025, 15:49 UTC

Winsten

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11 jul 2025, 15:41 UTC

Marktinformatie

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Peer Vergelijking

Prijswijziging

CareDx Inc Prognose

Koersdoel

By TipRanks

19.58% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 24.67 USD  19.58%

Hoogste 30 USD

Laagste 19 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor CareDx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

7 ratings

5

Buy

2

Hold

0

Sell

Technische score

By Trading Central

14.77 / 18.49Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

147 / 376 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.